A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

BackgroundThe use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge to overcome. Here, we report the...

Full description

Bibliographic Details
Main Authors: Ying Zhang, Jiaqi Li, Xiaoyan Lou, Xiaochen Chen, Zhou Yu, Liqing Kang, Jia Chen, Jin Zhou, Xiangping Zong, Zhen Yang, Minghao Li, Nan Xu, Sixun Jia, Hongzhi Geng, Guanghua Chen, Haiping Dai, Xiaowen Tang, Lei Yu, Depei Wu, Caixia Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
bispecific chimeric antigen receptor
CD19/22
relapsed or refractory
B cell non-Hodgkin lymphoma
cellular kinetics
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.664421/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.664421/full

Similar Items